ALTHEA GROUP HOLDINGS LIMITED (AGH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
AGH - ALTHEA GROUP HOLDINGS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.027
14 May |
0.002 OPEN $0.03 |
8.00% HIGH $0.03 |
1,085,724 LOW $0.03 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | -3.9 |
DPS All | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | 24.8 M |
Book Value Per Share | xxx | xxx | xxx | xxx | 7.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | -6.3 M |
Net Profit Margin | xxx | xxx | xxx | xxx | -55.29 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | -38.54 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | -35.65 % |
Return on Assets | xxx | xxx | xxx | xxx | -26.17 % |
Return on Equity | xxx | xxx | xxx | xxx | -38.54 % |
Return on Total Capital | xxx | xxx | xxx | xxx | -30.69 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -7.8 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | 4 M |
Long Term Debt | xxx | xxx | xxx | xxx | 1 M |
Total Debt | xxx | xxx | xxx | xxx | 5 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | 18 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 4 M |
Price To Book Value | xxx | xxx | xxx | xxx | 0.55 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | 1.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | 5.99 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | 28 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 9 M |
Research & Development | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
AGH STOCK CHART
FNArena News on AGH
1 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
2 |
Mainstreaming Marijuana: Not What You’d ExpectSep 28 2020 - Weekly Reports |
3 |
Australian Broker Call *Extra* Edition – Jul 20, 2020Jul 20 2020 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
2 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
3 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
4 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
5 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
6 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |